Top news of the week: 16.06.2020.

Finance, Biotechnology, Initial public offering, Medicine, Oncology, Myocardial infarction

Startups

On Jun 13, 2020
@IAmBiotech shared
[email protected] in @statnews: "I've always known deep down that the most effective use of my skills is to be an advocate for science and scientists, writ large. That has always been my passion: getting new medicine and new hope to patients." https://t.co/VM2pNzyYyC
Open

A pandemic, a funeral, and a chance to help heal the world

A pandemic, a funeral, and a chance to help heal the world

People tend to negotiate with themselves when faced with difficult situations. I did that with the start of the Covid-19 pandemic.

On Jun 12, 2020
@matthewherper shared
IPO dough! Royalty Pharma CEO is worth $2.2 billion, @nathanvardi writes. https://t.co/5ItmPIQpKd
Open

Meet The Secretive Wall Street Investor With The Billion Dollar Medicine Cabinet

Meet The Secretive Wall Street Investor With The Billion Dollar Medicine Cabinet

For 24 years, this former banker quietly purchased small slices of the most expensive and top-selling drugs in the nation and became a billionaire.

On Jun 15, 2020
@BiotechWorld shared
After a turbulent few months, Germany takes a stake in COVID-19 vaccine drugmaker CureVac https://t.co/vAbBW6CH8f
Open

After a turbulent few months, Germany takes a stake in COVID-19 vaccine drugmaker CureVac

After a turbulent few months, Germany takes a stake in COVID-19 vaccine drugmaker CureVac

Germany is taking a 23% stake in privately owned CureVac as it preps to push on with work for its mRNA vaccine against the COVID-19 pandemic.

On Jun 15, 2020
@BiotechWorld shared
Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work https://t.co/ugPlsG88iy https://t.co/sAExAXoKzO
Open

Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work

Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work

After getting off a $46 million series A in 2018, Texas-based biotech Shattuck Labs has followed up with a major $118 million second funding round.

On Jun 12, 2020
@GVteam shared
Founded by experts in cardiovascular medicine and human genetics, @VerveTx continues to advance gene editing medicines for heart disease – https://t.co/f08Pf2UNAn
Open

Verve banks $63M to move gene-editing heart attack treatment toward clinic

Verve banks $63M to move gene-editing heart attack treatment toward clinic

Verve Therapeutics launched last year with $58.5 million to create a one-and-done treatment to replace the array of drugs we use to treat heart disease. Now, it’s gearing up to move its ...

On Jun 15, 2020
@didierleconte shared
Investing in the biotech sector https://t.co/vwmhgTHPgl via @LinkedIn
Open

Investing in the biotech sector

Investing in the biotech sector

Proud of the past, rooted in the present and optimistic about the future  By Geneviève Guertin & Didier Leconte Recently we proudly announced the creation of an important life ...

On Jun 11, 2020
@matthewherper shared
Verve seeks to advance gene-editing treatment for heart disease https://t.co/YLlhPEKRuy
Open

Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease

Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease

The Cambridge, Mass.-based company, which was officially launched in May 2019, is working on a treatment that would use gene-editing to lower cholesterol.

On Jun 11, 2020
@BiotechWorld shared
Sanofi teams up with China biotech Alphamab for breast cancer R&D https://t.co/8VCJAV1uoX https://t.co/mUxQeiL5ho
Open

Sanofi teams up with China biotech Alphamab for breast cancer R&D

Sanofi teams up with China biotech Alphamab for breast cancer R&D

French Big Pharma Sanofi, looking to bolster its cancer R&D, has penned a new pact with Alphamab Oncology that focuses on HER2-positive breast cancer.